Terapet Company
Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qualγscan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.
Employee Number:
11-50
Headquarters:
Geneva, Geneve, Switzerland, Europe
Founded Date:
2019-12-19
Industry:
Imaging & Digital Pathology
Super Industry:
Diagnostics & Genomics
Investors:
Eurostars, FONGIT, Innosuisse, Nina Capital, Venture Kick
Ipo Status:
private
City:
Geneva
Region:
Geneve
Country:
Switzerland
Founders:
Christina Vallgren, Marcus Palm, Raymond Miralbell